Claire Immediato Daien (Claire Daien)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Rheumatoid Arthritis

Disease Activity

Chronic Lymphocytic Leukemia

Top Venues

Rheumatology (Oxford, England)

Annals of the rheumatic diseases

European journal of immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Rempenault Claire, Cédric Lukas, Léa Tardivon, Claire Immediato Daien, Bernard G Combe, Philippe Guilpain, Jacques Morel
Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease. RMD open 10 (1) (2024)
Rempenault Claire, Cédric Lukas, Léa Tardivon, Claire Immediato Daien, Bernard G Combe, Philippe Guilpain, Jacques Morel
Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease. RMD open 10 (1) (2024)
Rachel Audo, Pauline Sanchez, Benjamin Rivière, Julie Mielle, Jian Tan, Cédric Lukas, Laurence Macia, Jacques Morel, Claire Immediato Daien
Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control. Rheumatology (Oxford, England) (2022)
Rachel Audo, Pauline Sanchez, Benjamin Rivière, Julie Mielle, Jian Tan, Cédric Lukas, Laurence Macia, Jacques Morel, Claire Immediato Daien
Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control. Rheumatology (Oxford, England) (2022)
Julie Mielle, Jacques Morel, Jamila Elhmioui, Bernard Combe, Laurence Macia, Valérie Dardalhon, Naomi Taylor, Rachel Audo, Claire Immediato Daien
Glutamine promotes the generation of B10 + cells via the mTOR/GSK3 pathway. European journal of immunology 52 (3) (2022)
Claire Immediato Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study. Annals of the rheumatic diseases (2022)
Julie Mielle, Anaïz Nutz, Philippe Guillpain, Rachel Audo, Cécile Gaujoux-Viala, Bernard Combe, Jacques Morel, Claire Immediato Daien
IL-10-producing regulatory B cells are present and functional in primary Sjögren patients. Immunologic research 69 (1) (2021)